Chiral Benzodiazepinone Resolution Without SFC or HPLC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing chiral benzodiazepinone compounds, such as (2R,3S)-N-[(3S)-5-(3-Fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl) succinimide, are inefficient, time-consuming, and costly due to the use of expensive chromatographic techniques like SFC and HPLC, with a low theoretical yield of 50%.
Innovation Solution
A method involving the reaction of benzodiazepinone compounds with L-pyroglutamic acid or D-pyroglutamic acid, followed by base treatment and reaction with S(+)-camphor sulfonic acid, to produce chiral benzodiazepinone derivatives with high chiral purity and improved yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chiral chromatographic methods (SFC, HPLC) are used to prepare chiral benzodiazepinone compounds, then chiral purity is achieved, but production cost increases and productivity decreases
Solution Approach 1:
The patent extracts the chiral resolution step from the chromatographic process by using chiral derivatization agents (camphorsulfonic acid, tartaric acid, etc.) that form diastereomeric salts with the racemic mixture. These diastereomers have different solubilities and can be separated by simple filtration or crystallization, eliminating the need for expensive chromatographic equipment while maintaining high chiral purity
Solution Approach 2:
The patent introduces chiral derivatization agents as intermediary substances that temporarily modify the racemic compound into diastereomeric forms. These intermediaries (chiral acids or bases) enable separation through their differential solubility properties, after which they can be removed to yield the pure chiral product
2Manufacturing precision
If chiral chromatographic methods (SFC, HPLC) are used to prepare chiral benzodiazepinone compounds, then chiral purity is achieved, but production time increases
Solution Approach 1:
The patent removes the time-consuming chromatographic separation step by replacing it with rapid crystallization or filtration of diastereomeric salts. The chiral resolution is achieved through simple solid-liquid separation processes that take minutes or hours rather than the extended chromatographic runs required by SFC or HPLC
Solution Approach 2:
The patent performs chiral derivatization as a preliminary step before separation, converting the racemic mixture into diastereomeric salts that can be easily separated. This preliminary chemical modification enables subsequent rapid physical separation methods, avoiding the need for time-consuming chromatographic analysis and purification
3Manufacturing precision
If chiral chromatographic methods (SFC, HPLC) are used to prepare chiral benzodiazepinone compounds, then chiral purity is achieved, but production cost increases
Solution Approach 1:
The patent replaces expensive chromatographic equipment and consumables with inexpensive chiral derivatization agents and simple filtration/crystallization setups. The chiral acids or bases used for resolution are low-cost materials that can be easily handled with standard laboratory glassware, eliminating the need for expensive SFC or HPLC systems
Solution Approach 2:
The patent extracts the costly chromatographic separation process and replaces it with economical crystallization or filtration of diastereomeric salts. This substitution maintains high chiral purity while dramatically reducing equipment costs, material costs, and operational expenses associated with chromatographic methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves chiral purity greater than 99% and yields higher than 50%, providing a more efficient and cost-effective process for producing chiral benzodiazepinone compounds.
Implementation Method 1
reacting the compound of Formula (Ia) with L-pyroglutamic acid (L-PGA) to obtain a compound of Formula (Ib)
Implementation Method 2
reacting the compound of Formula (I) with S (+) camphor sulfonic acid (CSA) to provide a compound of Formula (Ic)
Data Source
AI summary
The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I) wherein: R1 each is independently F, Cl, Br, I, OCH3, CN or NO2; R2 each is independently identical or different C1-C5 alkyl; n1 is an integer between 1 and 5; and n2 is an integer between 1 and 4. In addition, the present invention provides a compound represented by the following structures: Compound (1a) and Compound (2), wherein X comprises: chloride, acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydroiodide, maleate, 2-hydroxyethanesulfonate, lactate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, sulfonate, tartrate, thiocyanate, toluenesulfonate, or undecanoate salt, or any combination thereof.